ABSTRACT-The insulinlike growth factor (IGF) family is believed to be important in en-
SEMINARS IN REPRODUCTIVE ENDOCRINOLOGY Volume 17, Number 1 1999
has been challenged in studies with the igf1null mouse. 7 Estradiol administration resulted in an increase in cells in the S-phase in both in wild-type and mutant mouse uterus. However, there was a profound decrease in cells in mitosis in all regions of the igf1 null uterus, compared to wild-type, suggesting that IGF-I is critically involved in the progression from S-phase through the G2/M phase of the cell cycle. 7 The IGF receptors have affinities for the IGFs in the range of 10 -9 to M. The type I IGF receptor is homologous with the insulin receptor and is the principal receptor for signal transduction via activation of the tyrosine kinase pathway. 8 Subsequent to insulin-receptor substrate phosphorylation, IGF mitogenic effects are primarily mediated via the MAP kinase pathway, whereas IGF metabolic effects are primarily mediated via the PI3 kinase pathway The type II IGF receptor is identical to the mannose-6-phosphate receptor, which shuttles IGF-II (and lysosomal enzymes) from the cell surface, participating in IGF-II turnover. 9 The type II receptor also mediates endothelial cell migration and induces neovascularization in the rat cornea. 10 This receptor has signaling properties via cGMP, 11 and in pancreatic cells mediates insulin exocytosis. 12 The six high-affinity IGFBPs bind IGFs with affinities in the range of 10 -11 to 10 -12 M and generally inhibit IGF availability to their receptors in target cells. Posttranslational IGFBP processing by proteolysis and glycosylation results in lowered IGFBP affinities for the IGFs, thereby increasing IGF availability to their receptors. IGFBP phosphorylation increases affinity for the IGFs and limits their access to their receptors. 1 A family of IGFBP proteases has been identified which are metal-dependent enzymes of the kallikrein, cathepsin, matrix metalloproteinase, and disintegrin metalloproteinase families. 2, 13 These enzymes have unique specificities for the IGFBPs, although IGFBP-1 is the most resistant to proteolysis. IGFBP-1 and IGFBP-3 also have IGF-independent actions, by binding to cell surfaces and affecting cellular motility and cellular mitosis, respectively 1 Recently, four IGFBP-related proteins (IGFBP-rP-14) have been described that bind IGFs with low affinities and uniquely bind insulin. 3 Their roles in IGF and insulin regulation await further investigation.
THE IGF FAMILY IN CYCLING ENDOMETRIUM
IGF peptides, IGFBPs, IGF receptors, and IGFBP proteases undergo unique changes during the menstrual cycle and in response to different hormonal stimuli of endometrial cells in vitro, suggesting unique functions for them under different steroid hormone conditions (Fig. 1 ).
14-23 IGF-I mRNA is preferentially expressed in mid-late proliferative and early secretory endometrium, and IGF-II mRNA is expressed preferentially in secretory endometrium. Because of its temporal expression, IGF-I is believed to mediate the mitotic actions of E 2 in this tissue. Indeed, IGF-I is stimulated by estradiol in endometrium of several species, including rodents, farm animals, and nonhuman primates. 7 For example, high levels of IGF-I mRNA are expressed in rat uterus, which increases 20-fold in response to exogenously administered E 2 .
24 IGF-I has also been implicated in estrogen-dependent neoplasms of human endometrium. 25 Thus, IGF-I is believed to be one of several mediators in mitogenic actions of estradiol to effect rapid endometrial growth. IGF-II, expressed abundantly in midlate secretory endometrium is believed to be a mediator of progesterone action. 26 The type I IGF receptor is preferentially expressed in glandular epithelium with lower amounts in stroma. 21 Since the IGF peptides are stromally derived, they likely participate in proliferation and cell survival of stroma and epithelium, by autocrine and paracrine mechanisms, respectively. IGF-I and IGF-II are mitogenic to in vitro cultured human endometrial cells and regulate secretory functions of stromal cells, 25, 26 supporting roles for these peptides in endometrium in vivo.
IGFBP-1-6 mRNAs are expressed in human endometrium, primarily in stroma. 21 IGFBP-5 is the only IGFBP that is expressed preferentially in proliferative phase endometrium. It is found in the ex-tracellular matrix of many tissues, where it is proteolyzed to release IGFs for local tissue action.
1 By analogy, IGFBP-5 may facilitate transport of the IGFs from their sites of synthesis to their sites of action during the proliferative phase of the cycle, although this has not been experimentally demonstrated. IGFBP-2, -3, -4, and -6 are differentially expressed in secretory phase endometrium where they likely regulate IGF actions locally. IGFBP-1 is the most abundantly expressed IGFBP and is a major protein product of secretory endometrium. It probably plays a major role in regulating IGF availability to receptors on both glandular epithelium and stroma during the secretory phase. In an IGFBP-1 transgenic mouse model, IGFBP-1 was abundantly expressed in the glandular epithelium, and impaired E 2 actions on uterine DNA synthesis, compared to wild-type controls, suggesting that IGF-I is a mediator of E 2 action in the rodent uterus. 27 IGFBP-4 protease activity has been identified in medium conditioned by human endometrial stromal cells decidualized in vitro. 28 It is a metal-dependent enzyme whose activity is also IGF-dependent. As with other IGFBP proteases, it likely keeps IGF availability to receptors in equilibrium. However, the in vivo production of IGFBP-4 protease activity and its physiological significance remain to be determined.
Human endometrial stromal cells decidualized in vitro also produce IGFBP-rP-1. 29 This protein is regulated (inhibited) by IGFs. The specificity of the production in endometrium is underscored by a lack of production of this protein by human cytotrophoblasts. Since the role of IGFBP-rPs is currently evolving, it will be of interest to see if IGFBPrp-1 has a role in regulation of IGF or insulin action in the endometrium.
THE IGF FAMILY IN AT THE DECIDUAL: TROPHOBLAST INTERFACE
IGF-II mRNA is expressed in secretory endometrium and in uterine decidua from ectopic pregnancies. 18, 21 However, IGF-II is not expressed in decidua of intrauterine gestations, but rather is exclusively expressed in the placenta. 22 ' 30 Abundant IGF-II expression has been noted in the columns of the intermediate (invading) trophoblasts in the anchoring villi. 22 There is a gradient of IGF-II mRNA expression in the columns, with greatest levels expressed at the invading front, suggesting a role for IGF-II in trophoblast invasion 22 ( Fig. 2 ).
IGF receptor mRNAs are expressed in placental trophoblasts, 22 suggesting that these cells are targets for IGF action. IGF-I inhibits aromatase activity in trophoblasts in suspension culture. 31 It also regulates glucose and amino acid transport in first trimester human placental trophoblasts. 32 In addition, IGF-I stimulates hCG production in choriocarcinoma cells. 33 These studies suggest that IGFs may play a role in trophoblast physiology and metabolism. In addition, the type II IGF receptor mediates the angiogenic actions of proliferin in rat cornea and stimulates endothelial cell migration in vitro. 10 Whether IGF-II acting via the type II receptor is an angiogenic factor at the maternakfetal interface or whether it is a mitogen, survival factor, or a regulator of trophoblast physiology remains to be determined.
IGFBPs in nonpregnant secretory phase endometrium are considerably upregulated in decid- 21 where they likely regulate IGF actions. The role of IGFBP-1 in implantation is considered in the next section.
SEMINARS IN REPRODUCTIVE ENDOCRINOLOGY
Studies with cytotrophoblast monolayer cultures and with decidualized endometrial stromal cells in culture demonstrate that the cytotrophoblast se cretes an IGFBP-3 protease. 34 The placenta thus ap pears to be the site of origin of the pregnancy serum IGFBP-3, which first appears in the maternal circulation at about 6 weeks of gestation and is barely detectable by 5 days postpartum. 35 ' 36 This protease decreases the affinity of IGFBP-3 for radio labeled IGF-II >IGF-I and increases IGF bioavail ability believed to be important in maternal tissue growth and perhaps placental growth. 13 ' 37 In clini cal situations of fetal growth restriction lower lev els of IGFBP-3 protease have been reported, and el evated levels have been observed in multiple gestations. 38 These observations are consistent with the placenta being the origin of the IGFBP-3 pro tease. This protease has recently been identified as a member of the disintegrin metalloproteinase (ADAM) family.
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IGFBP-1 AND IMPLANTATION
IGFBP-1, also known as placental protein-12 40 and α 1 -progesterone-dependent endometrial glob ulin (α 1 -PEG) 41 is not a placental product, but rather is exclusively made in endometrium of a va riety of species. 42 ' 43 In humans it is a major product of late secretory endometrium (16 µg/g protein), and is abundantly produced by maternal decidua, reaching levels of 1224 µg/g protein by midgestation, [44] [45] [46] [47] with concomitant marked induction of its mRNA. 14, 18, 21 Immunoreactive IGFBP-1 localizes to the extracellular matrix and stromal cells of decidualizing endometrium, in the periarteriolar regions, and on the villous trophoblast, but not on placental fibroblasts. [48] [49] [50] [51] [52] [53] During the invasive phase of im plantation, the "intermediate" trophoblast of the anchoring villous produces large amounts of IGF-II and invades into the maternal decidual stroma which is producing large amounts of IGFBP-1 22 ' 54 ( Fig. 2) . The spatial pattern and relative abundance of IGFBP-1 in decidua suggest it interacts with the IGF-II-expressing, invading trophoblast. IGF-II has been shown to increase cytotrophoblast motility, 55 and although its precise role in trophoblast inva sion is not known, its abundance at the invading front and the proximity of decidual cells expressing IGFBP-1 are suggestive of a role for this growth fac tor and its inhibitor in invasion. IGFBP-1 has been shown to have inhibitory effects on IGF binding and IGF actions on choriocarcinoma cells in cul ture, 33 and may have similar effects on IGF-II on normal, invading cytotrophoblasts at the maternalifetal interface in vivo.
IGFBP-1 also has IGF-independent actions, by binding to cell membranes and altering cellular motility. 56 IGFBP-1 contains the Arg-Gly-Asp (RGD) motif which is a recognition site for several cell adhesion molecules, including the a5bl integrin. IGFBP-1 binds to the α 5 β 1 integrin, presum ably via its RGD sequence, and stimulates motility of Chinese Hamster Ovary (CHO) cells in vitro. 56 In humans the invading trophoblast at the maternal: fetal interface uniquely expresses the α 5 β 1 integrin, among all trophoblast phenotypes. 57 Recent studies demonstrated that IGFBP-1 specifically binds to human trophoblasts and that it binds to the α 5 β 1 in tegrin in trophoblast membranes. 58 Furthermore, it inhibits trophoblast attachment to fibronectin, an other RGD ligand found in the placental bed. 58 Cy totrophoblast interaction with fibronectin, through the α 5 β 1 integrin, restrains invasion. 59 Human tro phoblasts do not invade into human endometrial stromal cell multilayer cultures decidualized in vitro, which produce high levels of IGFBP-1. 58 However, when IGFBP-1 production by the stromal cells is inhibited by insulin, it results in trophoblast invasion into the stromal multilayers. Furthermore, invasion is inhibited by the addition of exogenous IGFBP-1 into the coculture system, in a dose-de pendent fashion. These studies cumulatively sug gest that IGFBP-1 is a maternal "restraint" on tro phoblast invasion. Whether it does this via direct interactions with the trophoblast (as an α 5 β 1 ligand or a ligand for other cell surface proteins) or by in hibiting IGF-II actions on the trophoblast is not known at this time. The role of IGFBP-1 in implan tation, however, is currently controversial, since it has also been shown to stimulate migration of pas saged human trophoblasts across a Matrigel extra cellular matrix barrier in the presence of serum.
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In this experimental system IGF-II is also a stimula tor of passaged trophoblast migration and inva sion. 60 In primary trophoblast cultures, IGFBP-1 in creases total gelatinase activity, suggesting it enhances trophoblast invasiveness. 61 However, the specific enzyme(s) and/or inhibitors/activators re sponsible for this rise in gelatinase activity re mained unidentified, since IGFBP-1 showed no ef fect on MMP-2 or MMP-9 and increased TIMP-1 in these studies. 61 These seemingly conflicting obser vations likely depend on different experimental paradigms, cell populations, and endpoints for evaluating IGFBP-1 function. The role(s) of IGFBP-1, either as a direct modulator of trophoblast inva sion or as an IGF-II binding protein, at the maternakfetal interface should be forthcoming in the near future.
REGULATION OF IGFBP-1 IN ENDOMETRIUM
In vivo human endometrial stromal cells, after es trogen-priming, undergo proliferation and differen tiation in response to progesterone. Endometrial stromal cells can be decidualized in vitro with pro gesterone or progestins, or stimulators of cyclic AMP (cAMP), and estradiol and epidermal growth factor (EGF). 50, 62, 63 This in vitro model has provided an opportunity to investigate production and regu lation of IGFBP-1, which is produced primarily by this cell type in endometrium in vivo. IGFBP produc tion in endometrium is dependent on stromal differ entiation, 17, 20 and, while decidualized stromal cells increase their production of all IGFBPs upon decidualization in vitro, most striking are the high levels of IGFBP-1 (25 µg per day per 10 6 cells), in contrast to another decidual marker, prolactin (40 ng per 10 6 cells per day).
172064 Progesterone regulates IGFBP-1 protein and mRNA expression in decidualized en dometrial stromal cells, and the progesterone recep tor antagonist RU486 is inhibitory. 17, 64 The IGFBP-1 gene has a glucocorticoid response element and a steroid hormone response element, and it is likely that progesterone exerts its effects on IGFBP-1 gene expression via these promoter elements. 43 
Insulinlike Peptides
The close proximity of the IGF-II-producing trophoblast and the IGFBP-1-producing decidua sug gests either an effect of IGFBP-1 on the trophoblast and/or an effect of IGF-II on decidual (and/or tro phoblast) function. Insulin and IGFs are known in hibitors of IGFBP-1 in liver and HepG2 cells. 43 Sim ilarly, in endometrium, insulin, IGF-I, and IGF-II inhibit decidualizing stromal cell IGFBP-1 secretion into conditioned media (CM), 20 in a dose-depen dent fashion, with ED 50 's consistent with action through their cognate receptors. Insulinlike pep tides are also inhibitory to IGFBP-1 production by endometrial stromal cells decidualized in vivo. 65 The physiologic relevance of IGF regulation of IGFBP-1, a major product of secretory phase en dometrium and decidua, likely rests on the need to regulate IGF availability to target cells, including trophoblast and/or decidua and endometrial glan dular epithelium. In addition, these regulatory mechanisms may affect direct interactions of this IGFBP with the invading trophoblast (see above). However, the physiologic relevance of insulin reg ulation of IGFBP-1 production by endometrial stro mal cells or decidua is unresolved. In contrast to minute-to-minute changes in insulin and IGFBP-1 in the circulation, 43 it is unlikely that there are wildly fluctuating levels of IGFBP-1 at the deciduaktrophoblast interface throughout the day. How insulin action is controlled at the level of the en dometrium remains unresolved, although IGFBPrPs may be involved, as well as insulinases, and other modulators of insulin action. This question is particularly relevant for women with anovulatory infertility who have insulin resistance and hyperinsulinemia, as with polycystic ovary syndrome.
Cytokines, Growth Factors, and Chorionic Gonadotropin
The question naturally arises as to whether other growth factors and cytokines at the decidua: tro phoblast interface regulate IGFBP-1 production in the maternal compartment. A recent study investi gated the effects of several cytotrophoblast prod ucts on endometrial stromal IGFBP-1 production in vitro, including interleukin-ip (IL-1β), transform ing growth factor-β (TGF-β), stem cell factor (SCF), colony stimulating factor-1 (CSF-1), leukemia in hibitory factor (LIF), and IGF-II. 66 Only IGF-II and IL-1β had an effect; both were inhibitory, with ED 50 , s consistent with actions through their cog nate receptors. IL-1β has also inhibits the process of decidualization of endometrial stromal cells. 67 '
68
Since IL-1β stimulates production of trophoblast matrix metalloproteinase-9 (MMP-9) which pro motes the invasive trophoblast phenotype, 69 it is likely that inhibition of IGFBP-1 in the decidua by this cytokine further promotes trophoblast inva sion, by inhibiting this decidual "maternal restraint protein" (see below).
Human chorionic gonadotropin (hCG) stimu lates endometrial stromal IGFBP-1 production, likely due to its effects on promoting stromal decid ualization. 70, 71 Similar results have been reported with free hCG-a subunit, 72 although the mecha nisms for free α-subunit action are not well under stood. However, hCG has no appreciable effect on stromal cell products once the cells are decidual ized in vivo. 73 While the physiologic relevance of hCG action in endometrium is not well established, a premature luteinizing hormone (LH) surge may lead to premature decidualization of the endome trium (via untimely production of progesterone). Since elevated LH has been associated with an in creased risk of spontaneous abortion, 74 whether el evated endometrial IGFBP-1 predisposes to poor implantation and miscarriage is an important clini cal issue which remains to be resolved. Since IL-ip, IGF-II, and hCG are trophoblast-derived, these ob servations cumulatively support roles for select tro phoblast-derived growth factors and cytokines in the regulation of decidualization of the maternal endometrium and of maternally-derived IGFBP-1 at the trophoblastdecidual interface (Fig. 2) . This dialogue between the trophoblast and endometrium is likely to have importance in normal as well as in abnormal placentation.
Hypoxia
In pregnancies complicated by uteroplacental insufficiency, maternal and fetal circulating IGFBP-1 levels are markedly elevated. [75] [76] [77] [78] [79] Recently, our group has demonstrated that the IGFBP-1 gene has a hypoxia response element in intron l. 80 Regulation of this response by hypoxia was confirmed using a human hepatoma cell line, 80 and this response is augmented in the presence of cAMP. 81 Preliminary studies indicate that endometrial stromal cells, decidualized in vitro, respond to a chemical hypoxicant (CoCl 2 ) with a twofold increase in IGFBP-1 mRNA and a four-to sixfold increase in protein. 82 An elevation of IGFBP-1 at the decidua: trophoblast interface could result in shallow implantation, which could greatly compromise nutrient and oxygen transfer to the placenta and fetus, resulting in fetal growth restriction (also see below).
IGFBP-1 IN A HUMAN PREGNANCY DISORDER OF SHALLOW IMPLANTATION
Preeclampsia, a disorder specific to pregnancy, occurs in 5-10% of pregnant women, and in its severe form is a major cause of fetal and maternal morbidity and mortality. 83 Clinically, it is usually detected in the third trimester, and if left undiagnosed or untreated, can progress to maternal multiorgan failure, coagulopathy, seizures, and maternal and fetal death. In the severe form of the disorder there is generalized hypoxia within the placenta and decidua, 84 and abnormally shallow cytotrophoblast invasion into the uterine decidua. 85, 86 The latter is believed to result from abnormal trophoblast adhesion molecules 87 and/or from elevated decidual levels of IGFBP-1 preventing deeper trophoblast invasion. 53 In support of the latter hypothesis is the clinical finding that in pregnancies complicated by severe preeclampsia, maternal serum IGFBP-1 levels in the second and early third trimesters are about sixfold higher 53 and at term are about twofold higher than in normal pregnancies. [88] [89] [90] This is not a nonspecific elevation of hepatic-derived proteins, since maternal serum levels of IGFBP-3 (also of hepatic origin) are normal and IGFBP-3 is not a useful predictor of preeclampsia. 91 In addition, hepatic-derived IGF-I levels in the circulation are about half of control levels. 53 A significant correlation was observed between maternal diastolic blood pressure, aspartate transcarbamylase and IGFBP-1, suggesting that IGFBP-1 reflects severity of preeclampsia and hepatic involvement. 53 It is likely that elevated levels of IGFBP-1 in the circulation of women with severe preeclampsia derive from the liver and decidua. In decidua IGFBP-1 is found in the periarteriolar region. With enhanced vascular permeability and vasospasm, common in preeclampsia, escape from the decidua into the maternal circulation may occur, contributing to the observed elevated serum levels of this binding protein in this disorder. Higher levels of immunoreactive IGFBP-1 were observed at the deciduahplacental interface in pregnancies complicated by severe preeclampsia, compared to controls. 53 Recent preliminary observations of hypoxic induction of IGFBP-1 in the decidua (see above) support the hypothesis that IGFBP-1 is a maternal restraint protein that is part of the pathophysiology of preeclampsia. However, the decidual origin of the elevated IGFBP-1 at the decidualiplacental interface and in the maternal circulation in severe preeclampsia remains to be determined. In a recent longitudinal study, IGFBP-1 levels were found to be decreased in maternal serum in midgestation in women who subsequently developed mild preeclampsia. 92 It is likely that mild and severe preeclampsia are different disorders, and controversy still surrounds whether circulating IGFBP-1 early in gestation is a predictor of development of the more fulminant form of the disease later in gestation.-
SUMMARY
IGFs, their binding proteins, binding protein proteases, and receptors are complex participants in regulating cellular mitosis, survival, metabolism, motility, and migration. Endometrium is a dynamic tissue in which cyclic, steroid-dependence of these processes occurs. In addition, their participation at the deciduaktrophoblast interface appears to be important with regard to decidual and trophoblast function and physiology. While there are still gaps to fill in understanding the precise roles of some of the members of the IGF family in endometrial, decidual, and trophoblast cellular function, determining their roles in abnormal endometrial development and abnormal implantation remains a challenge for the future.
